- Home
- CBK vs AVTX Comparison
CBK vs AVTX Comparison
Compare CBK & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBK | AVTX |
|---|---|---|
| Founded | 1975 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.9M | 339.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | CBK | AVTX |
|---|---|---|
| Price | $26.95 | $15.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | 42.0K | ★ 823.9K |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | $8.05 | N/A |
| P/E Ratio | $9.10 | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $23.24 | $3.39 |
| 52 Week High | $27.83 | $20.72 |
Technical Indicators
Market Signals| Indicator | CBK | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 67.00 | 54.79 |
| Support Level | $23.90 | $15.36 |
| Resistance Level | $27.52 | $16.40 |
| Average True Range (ATR) | 0.83 | 1.31 |
| MACD | 0.22 | 0.27 |
| Stochastic Oscillator | 88.54 | 60.70 |
Price Performance
Historical ComparisonAbout CBK Commercial Bancgroup Inc.
Commercial Bancgroup Inc a bank holding company. Through its subsidiary it is a full-service community banking institution that offers traditional consumer and commercial products and services to serve businesses and individuals in select markets in Kentucky, North Carolina, and Tennessee. Its service areas in Tennessee are (i) the Nashville MSA, (ii) the Knoxville MSA, and (iii) the Tri-Cities MSA, and (iv) Claiborne County, Cocke County, Union County, and Hamblen County, and their surrounding areas.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).